15 January 2020 - PHARMAC is seeking proposals from pharmaceutical suppliers for new medicines that could help New Zealanders living with type 2 diabetes.
“The new medicines we are looking at are called SGLT-2 inhibitors, GLP-1 agonists and DPP-4 inhibitors. Evidence suggests these medicines do more than just reduce sugar levels in people with type 2 diabetes. They can also help address type 2 diabetes-related complications like kidney and heart disease”, explains PHARMAC deputy medical director Dr Peter Murray.
PHARMAC has been closely following the clinical evidence of these medicines as it has evolved. They have today issued a request for proposals to try and secure an affordable price for these medicines.